The Bio Medica Laboratories IPO is an SME public offering by Bio Medica Laboratories Limited, a pharmaceutical company engaged in manufacturing sterile injectable products. Through this public issue, the company plans to raise capital to strengthen its operations, expand manufacturing capabilities, and support future business growth.
Bio Medica Laboratories Limited manufactures a range of injectable pharmaceutical formulations supplied to healthcare institutions, pharmaceutical companies, and other customers. The company focuses on maintaining quality standards, following regulatory requirements, and improving manufacturing efficiency to meet industry demand.
India’s pharmaceutical industry continues to benefit from increasing healthcare expenditure, growing demand for medicines, expanding exports, and continuous investment in healthcare infrastructure. These developments create growth opportunities for pharmaceutical manufacturers with established production capabilities and quality-focused operations.
The company aims to enhance its manufacturing infrastructure, improve operational efficiency, and strengthen its financial position through the utilisation of IPO proceeds. These initiatives are expected to support its long-term business strategy and expand its presence in the pharmaceutical sector.
The Bio Medica Laboratories IPO offers investors an opportunity to participate in a company operating in India’s growing pharmaceutical manufacturing industry. Before investing, investors should carefully review the company’s financial performance, valuation, business strategy, industry outlook, growth prospects, and associated risks.
This review covers all the important aspects of the Bio Medica Laboratories IPO, including issue details, important dates, reservation, lot size, promoter holding, GMP, subscription status, allotment, listing performance, company profile, business model, financial information, objectives of the issue, strengths, risk factors, registrar details, and frequently asked questions.
Bio Medica Laboratories IPO Details
| Bio Medica Laboratories IPO Details | Information |
|---|---|
| IPO Name | Bio Medica Laboratories IPO |
| Company Name | Bio Medica Laboratories Limited |
| IPO Status | Listed |
| IPO Type | Book Building Issue |
| Category | SME IPO |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹132 to ₹139 Per Share |
| Issue Price | ₹139 Per Share |
| Issue Size | ₹52.43 Crore |
| Fresh Issue | 33,95,000 Equity Shares |
| Offer for Sale | 3,77,000 Equity Shares |
| Total Shares Offered | 37,72,000 Equity Shares |
| IPO Open Date | 21 May 2026 |
| IPO Close Date | 25 May 2026 |
| Basis of Allotment | 26 May 2026 |
| Refund Initiation | 27 May 2026 |
| Shares Credited to Demat | 27 May 2026 |
| Listing Date | 29 May 2026 |
| Listing Exchange | NSE SME |
| Lot Size | 1,000 Shares |
| Minimum Investment | ₹1,39,000 |
| Registrar | Bigshare Services Private Limited |
The public issue consists of a fresh issue of equity shares along with an offer for sale by certain existing shareholders. The funds raised through the fresh issue are intended to support the company’s expansion plans and other business requirements, while the proceeds from the offer for sale will be received by the respective selling shareholders.
After the subscription period concluded, the allotment process was completed in accordance with the applicable regulations. Shares allotted to successful applicants were credited to their demat accounts before listing, while refunds were processed for unsuccessful applicants.
Bio Medica Laboratories Limited operates in a highly regulated pharmaceutical industry where manufacturing standards, product quality, operational efficiency, and customer relationships play an important role in long-term business growth. Investors should evaluate these factors together with the company’s financial performance and future strategy before making an investment decision.
Bio Medica Laboratories IPO Dates & Timeline
The Bio Medica Laboratories IPO followed the standard SME IPO process, beginning with the opening of the subscription window and concluding with the listing of the company’s equity shares on the NSE SME platform. After the bidding period ended, the registrar completed the allotment process, initiated refunds for unsuccessful applicants, and credited shares to successful investors before listing.
| Event | Date |
|---|---|
| IPO Opening Date | 21 May 2026 |
| IPO Closing Date | 25 May 2026 |
| Basis of Allotment | 26 May 2026 |
| Refund Initiation | 27 May 2026 |
| Shares Credited to Demat Account | 27 May 2026 |
| Listing Date | 29 May 2026 |
| Listing Exchange | NSE SME |
Investors who received allotment had their shares credited to their demat accounts before the listing date, while refunds for unsuccessful applications were processed according to the IPO schedule.
Bio Medica Laboratories IPO Reservation
The Bio Medica Laboratories IPO allocated shares among different investor categories in accordance with SME IPO regulations. A separate allocation was also made for the market maker to support liquidity after listing.
| Investor Category | Reservation |
|---|---|
| Qualified Institutional Buyers (QIB) | Not More Than 50% of the Net Issue |
| Non-Institutional Investors (NII) | Not Less Than 15% of the Net Issue |
| Retail Individual Investors (RII) | Not Less Than 35% of the Net Issue |
| Market Maker | 1,89,000 Equity Shares |
The reservation structure allows participation from institutional, non-institutional, and retail investors while ensuring market-making support for smoother trading after listing.
Bio Medica Laboratories IPO Lot Size
The lot size specifies the minimum number of shares that investors could apply for in the IPO. Applications were accepted in multiples of the prescribed lot size.
| Application Category | Lots | Shares | Investment Amount |
|---|---|---|---|
| Retail Minimum | 1 | 1,000 | ₹1,39,000 |
| Retail Maximum | 1 | 1,000 | ₹1,39,000 |
| HNI/NII Minimum | 2 | 2,000 | ₹2,78,000 |
Investors applying for shares above the retail investment limit were considered under the Non-Institutional Investor category as per the applicable IPO regulations.
Bio Medica Laboratories IPO Promoter Holding
The promoters held a majority stake in Bio Medica Laboratories Limited before the public issue. Following the fresh issue of equity shares, their shareholding reduced due to dilution while they continued to retain control of the company.
| Particulars | Details |
|---|---|
| Promoter Holding Before IPO | 95.73% |
| Promoter Holding After IPO | 70.28% |
The post-issue promoter shareholding reflects the dilution resulting from the fresh issue while indicating the promoters’ continued involvement in the company’s management and long-term growth.
Bio Medica Laboratories IPO GMP
The Grey Market Premium (GMP) represents the unofficial price difference at which IPO shares may trade before they are listed on a stock exchange. As grey market transactions are outside the regulated market, GMP should be viewed only as an indication of market sentiment and not as a reliable predictor of listing performance.
The GMP of the Bio Medica Laboratories IPO varied during the pre-listing period based on investor demand and prevailing market conditions. While GMP may provide a general indication of market expectations, investors should base their investment decisions on the company’s financial performance, business model, valuation, industry outlook, and future growth potential.
Bio Medica Laboratories IPO Subscription Status
The Bio Medica Laboratories IPO received participation from Qualified Institutional Buyers (QIBs), Non-Institutional Investors (NIIs), and Retail Individual Investors (RIIs). Overall, the issue was subscribed 2.31 times, reflecting moderate investor interest during the bidding period.
| Category | Subscription (Times) |
|---|---|
| Qualified Institutional Buyers (QIB) | 15.94x |
| Non-Institutional Investors (NII) | 1.41x |
| Retail Individual Investors (RII) | 2.92x |
| Total Subscription | 2.31x |
The subscription data helps investors understand the demand generated during the IPO period. However, investment decisions should be based on a comprehensive evaluation of the company’s financial performance, valuation, business fundamentals, industry position, and long-term growth potential rather than subscription figures alone.
Bio Medica Laboratories IPO Allotment Status
The allotment process for the Bio Medica Laboratories IPO was completed after the subscription period ended. The registrar finalised the basis of allotment after reviewing all valid applications received from different investor categories.
Applicants were able to check their allotment status through the registrar’s official website using their PAN, application number, or DP/Client ID. Shares allotted to successful applicants were credited to their demat accounts before the listing date, while refunds were initiated for applicants who did not receive an allotment.
Bio Medica Laboratories IPO Listing Performance
The equity shares of Bio Medica Laboratories Limited were listed on the NSE SME platform after the completion of the IPO process. The stock debuted below its issue price, reflecting the market sentiment on the listing day.
| Particulars | Details |
|---|---|
| Issue Price | ₹139 Per Share |
| Listing Price | ₹111.20 Per Share |
| Listing Gain/Loss | -₹27.80 Per Share |
| Listing Gain/Loss (%) | -20.00% |
| Listing Exchange | NSE SME |
The shares listed at a discount to the issue price, indicating a weaker market response on the day of listing. However, listing performance reflects only the initial trading session and should not be considered the sole factor for evaluating the company’s long-term investment potential.
About Bio Medica Laboratories Limited
Bio Medica Laboratories Limited is engaged in the manufacturing of sterile injectable pharmaceutical formulations. The company supplies its products to pharmaceutical businesses and healthcare organisations while focusing on quality standards, regulatory compliance, and efficient manufacturing processes.
Its manufacturing facility is equipped to produce a range of injectable formulations in accordance with applicable industry requirements. The company continually works towards improving production efficiency, maintaining product quality, and meeting customer expectations.
Bio Medica Laboratories serves customers across domestic and international markets through its manufacturing capabilities and quality-focused operations. It also focuses on expanding its product portfolio and strengthening customer relationships to support sustainable business growth.
Business Model
Bio Medica Laboratories Limited operates a pharmaceutical manufacturing business centred on the production of sterile injectable formulations for healthcare and pharmaceutical companies.
The company’s business model is supported by the following activities:
- Manufacturing Operations – Production of sterile injectable formulations using quality-controlled manufacturing processes.
- Third-Party Manufacturing – Manufacturing pharmaceutical products for customers based on their specifications and regulatory requirements.
- Quality Management – Maintaining product quality through established manufacturing practices and compliance with applicable regulatory standards.
- Customer Relationships – Building long-term partnerships with pharmaceutical companies by delivering products consistently and on time.
- Operational Expansion – Enhancing manufacturing capabilities and production capacity to support future business requirements.
- Market Development – Expanding its presence in domestic and overseas markets by offering quality pharmaceutical manufacturing solutions.
The company aims to strengthen its position in the pharmaceutical manufacturing industry by improving operational efficiency, expanding production capabilities, and meeting the evolving needs of the healthcare sector.
Product Portfolio
Bio Medica Laboratories Limited manufactures a range of sterile injectable pharmaceutical formulations used across different therapeutic segments. The company focuses on producing quality pharmaceutical products that comply with applicable manufacturing and regulatory standards while serving the requirements of healthcare institutions and pharmaceutical companies.
The company’s major product categories include:
- Dry Powder Injections – Sterile injectable formulations supplied in powder form that require reconstitution before administration.
- Liquid Injections – Ready-to-use injectable medicines manufactured for various therapeutic applications.
- Lyophilized (Freeze-Dried) Injections – Specialised injectable products manufactured using freeze-drying technology to improve product stability and shelf life.
- Antibiotic Injectable Formulations – Injectable medicines developed for the treatment of bacterial infections across different therapeutic areas.
- Contract Manufacturing Services – Manufacturing pharmaceutical formulations for other pharmaceutical companies according to their product specifications and quality requirements.
The company continues to expand its product offerings by improving manufacturing capabilities, maintaining quality standards, and meeting the evolving requirements of domestic and international pharmaceutical markets.
Industry Overview
India has established itself as one of the world’s leading pharmaceutical manufacturing hubs, supplying medicines to both domestic and international markets. The sector contributes significantly to healthcare by manufacturing a wide range of pharmaceutical formulations, active pharmaceutical ingredients (APIs), vaccines, and specialty medicines.
Growing healthcare awareness, increasing healthcare expenditure, an ageing population, rising incidence of chronic diseases, and expanding access to medical services continue to support the long-term growth of the pharmaceutical industry. In addition, government initiatives encouraging domestic manufacturing and improved healthcare infrastructure have created favourable conditions for industry expansion.
Sterile injectable formulations represent an important segment of the pharmaceutical market as they are widely used in hospitals, emergency care, critical care, oncology, and various specialised treatment areas. Demand for high-quality injectable medicines continues to increase due to advancements in healthcare services and rising patient requirements.
The pharmaceutical industry is highly regulated and requires manufacturers to comply with stringent quality standards, regulatory approvals, and manufacturing guidelines. Companies that invest in modern production facilities, quality systems, research capabilities, and regulatory compliance are generally better positioned for sustainable growth.
Although the industry offers significant opportunities, companies also face challenges such as intense competition, changing regulatory requirements, pricing pressures, fluctuations in raw material costs, and compliance-related expenses. Maintaining operational efficiency, product quality, and customer confidence remains essential for long-term success.
Bio Medica Laboratories IPO Financial Information
The financial performance of Bio Medica Laboratories Limited provides insight into the company’s operational growth, profitability, and financial position during the reported financial years. Reviewing the financial statements enables investors to assess revenue trends, earnings, capital structure, and overall business performance.
The following financial information is based on the company’s restated financial statements included in the offer document.
Statement of Assets, Liabilities and Equity
| Particulars (₹ in Lakhs) | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Total Assets | 10,330.59 | 8,356.82 | 7,134.66 |
| Total Liabilities | 5,819.97 | 4,900.24 | 4,389.58 |
| Total Equity | 4,510.62 | 3,456.58 | 2,745.08 |
The balance sheet indicates the company’s financial position over the reported years. Growth in total assets and shareholders’ equity reflects the expansion of business operations and strengthening of the company’s financial base.
Statement of Profit and Loss
| Particulars (₹ in Lakhs) | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue from Operations | 15,427.38 | 13,216.41 | 11,489.74 |
| EBITDA | 2,576.84 | 2,031.72 | 1,712.64 |
| Profit Before Tax (PBT) | 1,867.15 | 1,452.36 | 1,176.24 |
| Profit After Tax (PAT) | 1,393.06 | 1,086.71 | 876.53 |
The company has reported growth in revenue and profitability across the reported financial years, reflecting expansion in business operations and improved operational performance.
Bio Medica Laboratories IPO Key Financial Ratios
| Ratio | FY2025 |
|---|---|
| EBITDA Margin | 16.70% |
| PAT Margin | 9.03% |
| Return on Equity (ROE) | 30.88% |
| Return on Capital Employed (ROCE) | 27.54% |
| Debt to Equity Ratio | 1.29 |
| Earnings Per Share (EPS) (₹) | 14.72 |
| Net Asset Value (NAV) (₹) | 47.67 |
The above financial ratios provide an overview of the company’s profitability, capital efficiency, leverage, and shareholder returns. Investors should analyse these financial indicators together with the company’s business model, valuation, industry outlook, and future growth strategy before making an investment decision.
Bio Medica Laboratories IPO Objects of the Issue
Bio Medica Laboratories Limited intends to utilise the proceeds from the IPO to strengthen its manufacturing operations, improve its financial position, and support future business expansion. The proposed utilisation of funds is in line with the objectives outlined in the offer document.
The primary objects of the issue include:
- Expansion of Manufacturing Facility – A portion of the IPO proceeds will be utilised to expand and upgrade the company’s manufacturing infrastructure, enabling it to enhance production capacity and operational efficiency.
- Repayment or Prepayment of Borrowings – The company proposes to use part of the funds to reduce certain outstanding borrowings, which may improve its capital structure and reduce finance costs.
- Working Capital Requirements – Funds will also be deployed towards meeting working capital needs required for procurement of raw materials, inventory management, and day-to-day business operations.
- General Corporate Purposes – A part of the proceeds will be utilised for administrative expenses, business development initiatives, and other corporate requirements.
- Issue-Related Expenses – The company will use a portion of the funds to meet expenses associated with the public issue.
The planned utilisation of the IPO proceeds is expected to strengthen Bio Medica Laboratories Limited’s manufacturing capabilities, improve financial flexibility, and support its long-term growth strategy.
Bio Medica Laboratories IPO Strengths
Bio Medica Laboratories Limited has developed its business around pharmaceutical manufacturing with a focus on sterile injectable formulations. Some of the key strengths of the company include:
- Specialised Manufacturing Expertise – The company focuses on manufacturing sterile injectable pharmaceutical formulations used in various therapeutic applications.
- Established Manufacturing Facility – Modern manufacturing infrastructure enables the company to maintain product quality and production efficiency.
- Quality and Regulatory Compliance – The company follows applicable quality standards and regulatory requirements for pharmaceutical manufacturing.
- Diversified Product Portfolio – Its range of injectable formulations allows the company to cater to different healthcare and pharmaceutical requirements.
- Long-Term Customer Relationships – Continued business with pharmaceutical companies and healthcare institutions supports recurring demand.
- Experienced Management Team – The promoters and senior management possess industry knowledge and operational experience that supports business growth.
- Growing Pharmaceutical Industry – Rising healthcare expenditure, increasing demand for medicines, and export opportunities continue to support industry expansion.
- Focus on Capacity Enhancement – Ongoing investments in manufacturing infrastructure are expected to improve operational capabilities and future growth.
Bio Medica Laboratories IPO Risk Factors
Before investing in the Bio Medica Laboratories IPO, investors should carefully consider the following risk factors:
- Regulatory Compliance Risk – The pharmaceutical industry is highly regulated, and any non-compliance with regulatory standards could impact manufacturing operations.
- Dependence on Manufacturing Facility – A significant portion of production is carried out at the company’s manufacturing facility, making uninterrupted operations important for business continuity.
- Raw Material Price Fluctuations – Variations in the prices or availability of pharmaceutical raw materials may affect production costs and profit margins.
- Intense Industry Competition – The company competes with several domestic and international pharmaceutical manufacturers across different product segments.
- Customer Concentration Risk – Dependence on a limited number of customers may impact revenue if business relationships change.
- Working Capital Requirements – The pharmaceutical manufacturing business requires adequate working capital to support production and inventory management.
- Technology and Product Development Risk – Continuous investment in manufacturing technology and product development is necessary to remain competitive.
- SME Platform Risks – Shares listed on the SME platform may experience relatively lower liquidity and higher price volatility compared to main-board listed companies.
Bio Medica Laboratories IPO Registrar Details
The registrar is responsible for managing IPO-related activities, including processing applications, finalising the basis of allotment, handling refunds, crediting shares to successful applicants’ demat accounts, and resolving investor queries.
| Particulars | Details |
|---|---|
| Registrar | Bigshare Services Private Limited |
| Website | https://www.bigshareonline.com |
| [email protected] |
Investors can contact the registrar for assistance regarding IPO applications, allotment status, refunds, demat credit, or other issue-related queries.
Bio Medica Laboratories IPO Conclusion
The Bio Medica Laboratories IPO offers investors an opportunity to invest in a pharmaceutical manufacturing company engaged in the production of sterile injectable formulations. The company operates in a sector that continues to benefit from increasing healthcare demand, expanding pharmaceutical manufacturing, and growing export opportunities.
The IPO proceeds are proposed to be utilised for expanding manufacturing capacity, reducing borrowings, supporting working capital requirements, and meeting general corporate purposes. These initiatives are expected to strengthen the company’s operational capabilities and support future growth.
At the same time, investors should evaluate risks relating to regulatory compliance, raw material availability, competition, customer concentration, and operational execution before making an investment decision.
Overall, the Bio Medica Laboratories IPO should be assessed based on its financial performance, valuation, business model, competitive position, industry outlook, and long-term growth prospects.
Bio Medica Laboratories IPO FAQs
What is the Bio Medica Laboratories IPO?
Bio Medica Laboratories IPO is an SME public issue through which Bio Medica Laboratories Limited raised capital to support business expansion, manufacturing growth, working capital requirements, and other corporate purposes.
What was the issue price of the Bio Medica Laboratories IPO?
The issue price of the Bio Medica Laboratories IPO was ₹139 per equity share.
What was the minimum lot size for the Bio Medica Laboratories IPO?
The minimum application consisted of 1,000 equity shares, requiring an investment of ₹1,39,000.
On which stock exchange is Bio Medica Laboratories listed?
The company’s equity shares are listed on the NSE SME platform.
Who was the registrar for the Bio Medica Laboratories IPO?
Bigshare Services Private Limited acted as the registrar to the issue.
What were the objectives of the Bio Medica Laboratories IPO?
The company proposed to utilise the IPO proceeds for manufacturing expansion, repayment or prepayment of borrowings, working capital requirements, general corporate purposes, and issue-related expenses.
What are the major risks associated with the Bio Medica Laboratories IPO?
Key risks include regulatory compliance requirements, raw material price fluctuations, customer concentration, intense competition, operational risks, and lower liquidity associated with SME-listed shares.
Should investors consider investing in the Bio Medica Laboratories IPO?
Investment decisions should be based on the company’s financial performance, valuation, business model, industry outlook, future growth potential, and the risks disclosed in the offer document.
